Inventor · disambiguated record
Philip E. Hass
Also filed as: HASS PHILIP · HASS PHILIP E
25 granted patents·19 pending applications·102 citations·filing 1999–2024
95Inventor score
Top patents by PatentIndex Score
44 records- 0195US9815880B2IL-22 Fc fusion proteinsGENENTECH INC·Filed 2016·Granted Nov 14, 2017·15 cites·18 claims
- 0292US10723795B2Anti-interleukin-33 antibodies and uses thereofGENENTECH INC·Filed 2018·Granted Jul 28, 2020·6 cites·67 claims
- 0392US8007791B2Prevention and treatment of complement-associated eye conditionsGENENTECH INC·Filed 2008·Granted Aug 30, 2011·26 cites·13 claims
- 0491US10160793B2Methods of treating inflammatory bowel disease using IL-22 Fc fusion proteinsGENENTECH INC·Filed 2014·Granted Dec 25, 2018·9 cites·30 claims
- 0590US10087227B2Nucleic acids encoding IL-22 Fc fusion proteinsGENENTECH INC·Filed 2016·Granted Oct 2, 2018·5 cites·26 claims
- 0687US8268310B2Prevention and treatment of complement-associated eye conditionsHASS PHILIP·Filed 2011·Granted Sep 18, 2012·12 cites·7 claims
- 0786US10093730B2Anti-interleukin-33 antibodies and uses thereofGENENTECH INC·Filed 2015·Granted Oct 9, 2018·6 cites·58 claims
- 0883US11725050B2Anti-interleukin-33 antibodies and uses thereofGENENTECH INC·Filed 2020·Granted Aug 15, 2023·1 cites·28 claims
- 0981US11155591B2Methods of treating acute pancreatitis using IL-22 fc fusion proteinsGENENTECH INC·Filed 2018·Granted Oct 26, 2021·1 cites·27 claims
- 1078US2023063741A1IL-22 POLYPEPTIDES AND IL-22 Fc FUSION PROTEINS AND METHODS OF USEGENENTECH INC·Filed 2022·Application pending·0 cites
- 1177US7354585B2Methods of treating coagulapathic or thrombotic disordersGENENTECH INC·Filed 2006·Granted Apr 8, 2008·2 cites·15 claims
- 1277US2022213183A1Il-17a/f heterologous polypeptides and therapeutic uses thereofNOVARTIS PHARMA AG·Filed 2021·Application pending·0 cites
- 1377US2022213184A1Il-17a/f heterologous polypeptides and therapeutic uses thereofNOVARTIS PHARMA AG·Filed 2021·Application pending·0 cites
- 1476US10011654B2Antibodies directed to IL-17A/IL-17F heterodimersGENENTECH INC·Filed 2014·Granted Jul 3, 2018·1 cites·7 claims
- 1574US8497094B2Prevention and treatment of complement-associated eye conditionsHASS PHILIP·Filed 2012·Granted Jul 30, 2013·2 cites·9 claims
- 1674US2020385452A1Il-17a/f heterologous polypeptides and therapeutic uses thereofNOVARTIS PHARMA AG·Filed 2019·Application pending·0 cites
- 1773US7930109B2Crystal structure of CRIg and C3b:CRIg complexGENENTECH INC·Filed 2009·Granted Apr 19, 2011·1 cites·15 claims
- 1872US10961313B2Anti-factor D antibody variant conjugates and uses thereofGENENTECH INC·Filed 2019·Granted Mar 30, 2021·0 cites·41 claims
- 1972US2020377584A1Il-17a/f heterologous polypeptides and therapeutic uses thereofNOVARTIS PHARMA AG·Filed 2020·Application pending·0 cites
- 2071US11332507B2IL-22 Fc fusion proteinsGENENTECH INC·Filed 2018·Granted May 17, 2022·0 cites·13 claims
- 2171US11130791B2Methods for treating metabolic syndrome using IL-22 Fc fusion proteinsGENENTECH INC·Filed 2018·Granted Sep 28, 2021·0 cites·29 claims
- 2271US2020377585A1Il-17a/f heterologous polypeptides and therapeutic uses thereofNOVARTIS PHARMA AG·Filed 2020·Application pending·0 cites
- 2369US11136365B2Methods for preventing or treating cardiovascular conditions using il-22 fc fusion proteinsGENENTECH INC·Filed 2018·Granted Oct 5, 2021·0 cites·28 claims
- 2468US10179821B2Anti-factor D antibodiesGENENTECH INC·Filed 2015·Granted Jan 15, 2019·1 cites·9 claims
- 2567US2019100583A1Il-17a/f heterologous polypeptides and therapeutic uses thereofGENENTECH INC·Filed 2018·Application pending·0 cites
- 2667US2024327528A1Tie2-binding agents and methods of useGENENTECH INC·Filed 2024·Application pending·0 cites
- 2765US10584155B2Pharmaceutical compositions of IL-22 Fc fusion proteinsGENENTECH INC·Filed 2017·Granted Mar 10, 2020·0 cites·29 claims
- 2864US10544198B2Methods of accelerating or improving wound healing using IL-22 FC fusion proteinsGENENTECH INC·Filed 2017·Granted Jan 28, 2020·0 cites·40 claims
- 2962US6624295B1Human anti-factor IX/IXa antibodiesGENENTECH INC·Filed 1999·Granted Sep 23, 2003·14 cites·8 claims
- 3060US2013302333A1Prevention and treatment of complement-associated eye conditionsGENENTECH INC·Filed 2013·Application pending·0 cites
- 3159US11999787B2Tie2-binding agents and methods of useGENENTECH INC·Filed 2021·Granted Jun 4, 2024·0 cites·30 claims
- 3259US2018079826A1Prevention and treatment of complement-associated eye conditionsGENENTECH INC·Filed 2017·Application pending·0 cites
- 3358US7776573B2Crystal structure of CRIg and C3b:CRIg complexGENENTECH INC·Filed 2007·Granted Aug 17, 2010·0 cites·4 claims
- 3458US2006270003A1IL-17A/F heterologous polypeptides and therapeutic uses thereofGENENTECH INC·Filed 2004·Application pending·0 cites
- 3558US2017073409A1Il-17a/f heterologous polypeptides and therapeutic uses thereofGENENTECH INC·Filed 2015·Application pending·0 cites
- 3658US2008161540A1IL-17A/F heterologous polypeptides and therapeutic uses thereofARNOTT DAVID P·Filed 2007·Application pending·0 cites
- 3755US7049411B2Human anti-factor IX/IXa antibodiesGENENTECH INC·Filed 2003·Granted May 23, 2006·0 cites·20 claims
- 3855US2016272726A1Prevention and treatment of complement-associated eye conditionsGENENTECH INC·Filed 2016·Application pending·0 cites
- 3955US2007160576A1IL-17A/F heterologous polypeptides and therapeutic uses thereofGENENTECH INC·Filed 2006·Application pending·0 cites
- 4054US2022204606A1Il-17a/f heterologous polypeptides and therapeutic uses thereofNOVARTIS PHARMA AG·Filed 2021·Application pending·0 cites
- 4151US10654932B2Anti-factor D antibody variant conjugates and uses thereofGENENTECH INC·Filed 2016·Granted May 19, 2020·0 cites·41 claims
- 4249US2018355009A1IL-22 Fc FUSION PROTEIN AND METHODS OF USEGENENTECH INC·Filed 2018·Application pending·0 cites
- 4349US2017291940A1Il-17a/f heterologous polypeptides and therapeutic uses thereofGENENTECH INC·Filed 2016·Application pending·0 cites
- 4448US2011318301A1Il-17a/f heterologous polypeptides and therapeutic uses thereofARNOTT DAVID P·Filed 2011·Application pending·0 cites
Join the waitlist — get patent alerts
Get an alert when Philip E. Hass files or is granted a new patent.
We store only your email — no account needed. See our privacy policy.
Identity basis: PatentsView inventor disambiguation (2025Q4-odp release). How scoring works →